Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aliskiren once-daily versus twice-daily dosing in essential hypertension
2007-002469-11Phase 4Completed
- Sponsor
- Novartis
- Start
- Feb 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of aliskiren in essential hypertension (2 arms), sponsored by Novartis. Primary endpoint: Change in 24-hour mean ambulatory diastolic blood pressure. Started Feb 2008; status: completed.
02
Drugs
aliskiren
03
Conditions
essential hypertension
Beyond the preview
Go deeper on 2007-002469-11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002469-11.